Abstract
Introduction: Studies are needed to understand the role of CD34 expressing cells with regard to efficient engraftment, especially in the adjuvant treatment of cancer. Materials and Methods: In this study we have used a modified method in our laboratory for routinely counting CD34+ cells. Unlysed whole blood samples were stained with the DNA-selective and cell membrane-permeant Vibrant DyeCycle Violet stain. Results: CD34+ cells exhibit a consistent and differential Vybrant Dye Cycle Violet staining pattern. Based on their different DCV intensity, we classified these subpopulations as CD34+/DCVhigh and CD34+/DCVlow cells. In general, DCVhigh cells are about 12-times brighter than DCVlow cells. Conclusion: DCV staining may be used to discriminate subsets of CD34+ cells similarly to other methods which have previously defined different functional properties that can be related to the characterization, resolution, and purification of primitive hematopoietic stem cells in combination with specific useful markers for multicolor flow cytometric measurements.
Keywords: CD34, flow cytometry, P-glycoprotein, Stem cells, Vybrant DyeCycle Violet.
Current Stem Cell Research & Therapy
Title:Vybrant DyeCycle Violet Stain Discriminates Two Different Subsets of CD34+ Cells
Volume: 11 Issue: 1
Author(s): Cristian Nunez-Espinosa, María D. Garcia-Godoy, Ines Ferreira, Juan G. Rios-Kristjansson, David Rizo-Roca, Laura G. Rico, Gerard Rubi-Sans, Carlos Palacio, Joan R. Torrella, Teresa Pages, Mike D. Ward, Gines Viscor and Jordi Petriz
Affiliation:
Keywords: CD34, flow cytometry, P-glycoprotein, Stem cells, Vybrant DyeCycle Violet.
Abstract: Introduction: Studies are needed to understand the role of CD34 expressing cells with regard to efficient engraftment, especially in the adjuvant treatment of cancer. Materials and Methods: In this study we have used a modified method in our laboratory for routinely counting CD34+ cells. Unlysed whole blood samples were stained with the DNA-selective and cell membrane-permeant Vibrant DyeCycle Violet stain. Results: CD34+ cells exhibit a consistent and differential Vybrant Dye Cycle Violet staining pattern. Based on their different DCV intensity, we classified these subpopulations as CD34+/DCVhigh and CD34+/DCVlow cells. In general, DCVhigh cells are about 12-times brighter than DCVlow cells. Conclusion: DCV staining may be used to discriminate subsets of CD34+ cells similarly to other methods which have previously defined different functional properties that can be related to the characterization, resolution, and purification of primitive hematopoietic stem cells in combination with specific useful markers for multicolor flow cytometric measurements.
Export Options
About this article
Cite this article as:
Nunez-Espinosa Cristian, Garcia-Godoy D. María, Ferreira Ines, Rios-Kristjansson G. Juan, Rizo-Roca David, Rico G. Laura, Rubi-Sans Gerard, Palacio Carlos, Torrella R. Joan, Pages Teresa, Ward D. Mike, Viscor Gines and Petriz Jordi, Vybrant DyeCycle Violet Stain Discriminates Two Different Subsets of CD34+ Cells, Current Stem Cell Research & Therapy 2016; 11 (1) . https://dx.doi.org/10.2174/1574888X10666150528152547
DOI https://dx.doi.org/10.2174/1574888X10666150528152547 |
Print ISSN 1574-888X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3946 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Azoles as Effective Antifungal Agents: Trends, Scope and Relevance
The Natural Products Journal Synthesis and Antiproliferative Assay of Norcantharidin Derivatives in Cancer Cells
Medicinal Chemistry Future Prospects for Targeted Alpha Therapy
Current Radiopharmaceuticals The use of nanocarriers in acute myeloid leukaemia therapy: challenges and current status.
Current Pharmaceutical Biotechnology Dexrazoxane for the Prevention of Cardiac Toxicity and Treatment of Extravasation Injury from the Anthracycline Antibiotics
Current Pharmaceutical Biotechnology Haploidentical Stem Cell Transplantation in Childhood
Current Cancer Therapy Reviews Targeting the p53-Family in Cancer and Chemosensitivity: Triple Threat
Current Drug Targets Germinal and Somatic Trisomy 21 Mosaicism: How Common is it, What are the Implications for Individual Carriers and How Does it Come About?
Current Genomics Preclinical Studies of PROTACs in Hematological Malignancies
Cardiovascular & Hematological Disorders-Drug Targets Recent Patents Reveal Microtubules as Persistent Promising Target for Novel Drug Development for Cancers
Recent Patents on Anti-Infective Drug Discovery Cyclopentenyl Cytosine (CPEC): An Overview of its in vitro and in vivo Activity
Current Cancer Drug Targets Stem Cell Transplantation and MBL Replacement Therapy
Current Stem Cell Research & Therapy Treatment Strategies for Multiple Myeloma in the Age of Novel Therapies
Current Cancer Therapy Reviews Human Mesenchymal Stem Cells (hMSCs) as Targets of DNA Damaging Agents in Cancer Therapy
Current Cancer Drug Targets Hepatitis C Virus Infection and Antiviral Treatment in Marginal Zone Lymphomas
Current Clinical Pharmacology Progress in the Development of Selective Inhibitors of Aurora Kinases
Current Topics in Medicinal Chemistry CDK-associated Cullin 1 Promotes Cell Proliferation and Inhibits Cell Apoptosis in Human Glioblastoma
Current Cancer Drug Targets Apoptosis Suppression by Candidate Oncogene PLAC8 is Reversed in Other Cell Types
Current Cancer Drug Targets Flt3 Receptor Tyrosine Kinase as a Drug Target in Leukemia
Current Pharmaceutical Design The Management of Membranous Glomerulopathy in Allogeneic Stem Cells Transplantation: Updated Literature
Cardiovascular & Hematological Agents in Medicinal Chemistry